| Adding L-carnitine to clomiphene resistant PCOS women improves the quality of ovulation and the pregnancy rate. A randomized clinical trial 2014 · Group A · Women with clomiphene-resistant PCOS | 3 g | — | 85 |
| Three-year survival of patients with heart failure caused by dilated cardiomyopathy and L-carnitine administration 2000 · L-carnitine group · Adults with moderate to severe heart failure (NYHA class III to IV) caused by dilated cardiomyopathy | 2 g | 1026 days | 37 |
| Prevention by L-carnitine of interleukin-2 related cardiac toxicity during cancer immunotherapy 1993 · IL-2 plus L-carnitine · Advanced cancer patients with clinically important cardiac diseases | 1 g | 6 weeks | 15 |
| Protective Effects of L-Carnitine Against Delayed Graft Function in Kidney Transplant Recipients: A Pilot, Randomized, Double-Blinded, Placebo-Controlled Clinical Trial 2017 · L-carnitine group · Patients older than 14 years undergoing their first deceased-donor kidney transplantation | 3 g | 4 days | — |
| [L-carnitine improves sperm acrosin activity in male infertility patients] 2018 · LC group · Male infertility patients with low sperm acrosin activity; age not reported | 3 g | 90 days | 180 |
| A study on the efficacy and safety assessment of propionyl-L-carnitine tablets in treatment of intermittent claudication 2013 · PLC group · Chinese patients with intermittent claudication | 2 g | 120 days | 120 |
| The therapeutic effect of L-carnitine in patients with exercise-induced stable angina: a controlled study 1991 · L-carnitine group · Adults aged 40–65 with exercise-induced stable angina | 2 g | 26 weeks | 100 |
| Effect of L-carnitine on quality of life in covert hepatic encephalopathy: a randomized, double-blind, placebo-controlled study 2022 · L-carnitine group · Adults aged 19–65 with liver cirrhosis and covert hepatic encephalopathy | 2 g | 24 weeks | 70 |
| Multi-pharmacological treatment for young subfertile males with chronic prostatitis/chronic pelvic pain syndrome 2024 · group 2 (L-carnitine) · Males aged 28–40 with chronic prostatitis/chronic pelvic pain syndrome and subfertility | 2 g | 90 days | 50 |
| Multi-pharmacological treatment for young subfertile males with chronic prostatitis/chronic pelvic pain syndrome 2024 · group 4 (tadalafil/L-carnitine) · Males aged 28–40 with chronic prostatitis/chronic pelvic pain syndrome and subfertility | 2 g | 90 days | 50 |
| Adding L-carnitine to antagonist ovarian stimulation doesn't improve the outcomes of IVF/ ICSI cycle in patients with polycystic ovarian syndrome: a double-blind randomized clinical trial 2024 · L-carnitine group · Women aged 20–37 with PCOS-related infertility undergoing IVF/ICSI | 3 g | 8 weeks | 47 |
| Additional L-Carnitine Reduced the Risk of Hospitalization in Patients with Overt Hepatic Encephalopathy on Rifaximin 2022 · group B · Patients with overt hepatic encephalopathy receiving rifaximin | 1.5 g | 12 weeks | 41 |
| Randomised clinical trial: the efficacy and safety of propionyl-L-carnitine therapy in patients with ulcerative colitis receiving stable oral treatment 2011 · PLC 1 g/day group · Adults aged 18–75 with mild-to-moderate ulcerative colitis receiving stable oral aminosalicylate or thiopurine therapy | 1 g | — | 40 |
| Randomised clinical trial: the efficacy and safety of propionyl-L-carnitine therapy in patients with ulcerative colitis receiving stable oral treatment 2011 · PLC 2 g/day group · Adults aged 18–75 with mild-to-moderate ulcerative colitis receiving stable oral aminosalicylate or thiopurine therapy | 2 g | — | 39 |
| Additional antiischemic effects of long-term L-propionylcarnitine in anginal patients treated with conventional antianginal therapy 1995 · L-propionylcarnitine · Patients with at least 2 anginal attacks per week and objective signs of ischemia with angina during bicycle exercise testing | 1.5 g | 6 weeks | 37 |
| The effect of L-Carnitine supplementation on clinical symptoms, C-reactive protein and malondialdehyde in obese women with knee osteoarthritis: a double blind randomized controlled trial 2021 · L-carnitine group (LCG) · Women aged 45 years or older with obesity (BMI 25–35 kg/m²) and diagnosed knee osteoarthritis | 1 g | 12 weeks | 34 |
| L-Carnitine supplementation improved clinical status without changing oxidative stress and lipid profile in women with knee osteoarthritis 2015 · L-carnitine group · Overweight or obese women with mild to moderate knee osteoarthritis | 750 mg | 8 weeks | 33 |
| L-Carnitine treatment reduces severity of physical and mental fatigue and increases cognitive functions in centenarians: a randomized and controlled clinical trial 2007 · levocarnitine group · centenarians with fatigue onset after even slight physical activity; sex not reported | 2 g | — | 32 |
| The effects of L-carnitine treatment on left ventricular function and erythrocyte superoxide dismutase activity in patients with ischemic cardiomyopathy 2000 · Group I · Adults with ischemic cardiomyopathy; mean age 64.3 years; 27 men and 4 women | 2 g | 30 days | 31 |
| Controlled study on the therapeutic efficacy of propionyl-L-carnitine in patients with congestive heart failure 1992 · propionyl-L-carnitine · Men and women aged 48–73 years with mild to moderate (NYHA class II and III) congestive heart failure, receiving chronic digitalis and diuretics treatment | 1.5 g | 180 days | 30 |
| L-Carnitine in the treatment of fatigue in adult celiac disease patients: a pilot study 2007 · L-carnitine group · Adults with celiac disease | 2 g | 180 days | 30 |
| Effects of carnitine supplementation on flow-mediated dilation and vascular inflammatory responses to a high-fat meal in healthy young adults 2008 · L-Carnitine trial · Healthy men and women, mean age 30 ± 8 years | 2 g | 3 weeks | 30 |
| L-carnitine supplementation for the management of fatigue in patients with hypothyroidism on levothyroxine treatment: a randomized, double-blind, placebo-controlled trial 2016 · L-carnitine · Adults with hypothyroidism on levothyroxine treatment who continued to experience fatigue; mean age 50.0 years, 3 males and 57 females across the trial | 1.98 g | 12 weeks | 30 |
| L-carnitine treatment in patients with mild diastolic heart failure is associated with improvement in diastolic function and symptoms 2010 · L-carnitine group · Adults with NYHA class II symptoms, ejection fraction >45%, and documented grade 1 diastolic dysfunction | 1.5 g | 90 days | 29 |
| L-carnitine moderately improves the exercise tolerance in chronic stable angina 2000 · L-carnitine · Patients aged 56 ± 8 years with chronic stable angina; 30 men and 17 women across the study | 2 g | 90 days | 28 |
| Effects of oral L-carnitine administration in narcolepsy patients: a randomized, double-blind, cross-over and placebo-controlled trial 2013 · L-carnitine treatment period · Adults aged 20 years or older with narcolepsy with cataplexy | 510 mg | 8 weeks | 28 |
| Efficacy of L-carnitine supplementation on frailty status and its biomarkers, nutritional status, and physical and cognitive function among prefrail older adults: a double-blind, randomized, placebo-controlled clinical trial 2016 · L-carnitine group · Community-dwelling Malaysian adults aged 60 years and older with prefrailty; men and women | 1.5 g | 10 weeks | 26 |
| [The clinical and hemodynamic effects of propionyl-L-carnitine in the treatment of congestive heart failure] 1992 · propionyl-L-carnitine group · Men and women aged 48–69 with mild-moderate congestive heart failure | 2 g | 26 weeks | 25 |
| Ameliorating effects of L-carnitine and synbiotic co-supplementation on anthropometric measures and cardiometabolic traits in women with obesity: a randomized controlled clinical trial 2023 · L-carnitine + placebo · Women aged 19–49 with obesity (BMI 30–35 kg/m²), without the listed comorbidities | 1 g | 8 weeks | 22 |
| Prolonged oral L-carnitine substitution increases bicycle ergometer performance in patients with severe, ischemically induced cardiac insufficiency 1999 · L-carnitine group · Patients with NYHA class II or III cardiac insufficiency | 3 g | 120 days | 20 |
| Preliminary observations on the use of propionyl-L-carnitine in combination with sildenafil in patients with erectile dysfunction and diabetes 2004 · Group 1 · Men with type 1 or type 2 diabetes and medically documented erectile dysfunction, unresponsive to sildenafil monotherapy; age not reported | 2 g | 24 weeks | 20 |
| [L-carnitine treatment patients with chronic cerebral ischemia] 2013 · First group · Adults aged 42–74 with dementia-stage chronic cerebral ischemia | 1 g | 60 days | 20 |
| [L-carnitine treatment patients with chronic cerebral ischemia] 2013 · Second group · Adults aged 42–74 with dementia-stage chronic cerebral ischemia | 2 g | 60 days | 20 |
| Involvement of impaired carnitine-induced fatty acid oxidation in experimental and human diabetic kidney disease 2025 · oral L-carnitine treatment group · Adults aged 20 or older undergoing peritoneal dialysis | 2.25 g | 26 weeks | 13 |
| The effects of acute L-carnitine supplementation on endurance performance of athletes 2014 · LK-3 · Candidate professional male footballers; age and health condition not stated | 3 g | 1 day | 12 |
| Effect of L-carnitine on exercise performance in patients with mitochondrial myopathy 2015 · L-carnitine · Patients older than 14 years with biopsy-proven mitochondrial myopathy, chronic progressive external ophthalmoplegia, and exercise intolerance, mild fixed limb weakness, or myalgias | 3 g | 8 weeks | 12 |
| Carnitine supplementation improves metabolic flexibility and skeletal muscle acetylcarnitine formation in volunteers with impaired glucose tolerance: A randomised controlled trial 2019 · IGT carnitine · Adults aged 61–62 years, men and women, with impaired glucose tolerance | 2 g | 36 days | 11 |
| Usefulness of L-carnitine, a naturally occurring peripheral antagonist of thyroid hormone action, in iatrogenic hyperthyroidism: a randomized, double-blind, placebo-controlled clinical trial 2001 · Group A2 · Women receiving a fixed TSH-suppressive dose of L-T4, with iatrogenic hyperthyroidism | 2 g | 60 days | 10 |
| Usefulness of L-carnitine, a naturally occurring peripheral antagonist of thyroid hormone action, in iatrogenic hyperthyroidism: a randomized, double-blind, placebo-controlled clinical trial 2001 · Group B2 · Women receiving a fixed TSH-suppressive dose of L-T4, with iatrogenic hyperthyroidism | 2 g | 120 days | 10 |
| Influence of L-carnitine administration on maximal physical exercise 1990 · L-carnitine · Moderately trained young men; exact age and condition not reported | 2 g | 1 day | 10 |
| Effects of L-carnitine L-tartrate supplementation on muscle oxygenation responses to resistance exercise 2008 · LCLT trial · Healthy, previously resistance-trained men; mean age 25.2 years | 2 g | 23 days | 9 |
| Effects of L- and DL-carnitine on patients with impaired exercise tolerance 1995 · L-carnitine treatment group · Adults with cardiac disease and impaired exercise tolerance; age range and sex not reported | 900 mg | 2 weeks | 9 |
| Effects of propionyl-L-carnitine on peripheral arterial obliterative disease of the lower limbs: a double-blind clinical trial 1999 · propionyl-L-carnitine group · Patients with class II Fontaine peripheral arterial obliterative disease of the lower limbs | 3 g | 90 days | — |
| Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication 2001 · propionyl-L-carnitine group · Patients with disabling claudication | 2 g | 26 weeks | — |
| Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia 2005 · L-carnitine · Men aged 20–40 years with idiopathic asthenozoospermia | 3 g | 26 weeks | — |
| L-carnitine as an ergogenic aid for patients with chronic obstructive pulmonary disease submitted to whole-body and respiratory muscle training programs 2006 · L-carnitine group (CG) · Adults with moderate-to-severe chronic obstructive pulmonary disease; mean age 66 ± 7 years | 2 g | 6 weeks | — |
| L-carnitine supplementation to diet: a new tool in treatment of nonalcoholic steatohepatitis--a randomized and controlled clinical trial 2010 · L-carnitine plus diet · Patients with nonalcoholic steatohepatitis (NASH); age and sex not stated | 2 g | 24 weeks | — |
| Sibutramine and L-carnitine compared to sibutramine alone on insulin resistance in diabetic patients 2010 · sibutramine plus L-carnitine · Patients with uncontrolled type 2 diabetes mellitus (HbA1c >8.0%); age and sex not stated | 2 g | 1 year | — |
| Comparison between orlistat plus l-carnitine and orlistat alone on inflammation parameters in obese diabetic patients 2011 · orlistat plus L-carnitine · Adults with obese type 2 diabetes mellitus and HbA1c >8.0% | 2 g | 1 year | — |
| L-Carnitine plus cilostazol versus cilostazol alone for the treatment of claudication in patients with peripheral artery disease: a multicenter, randomized, double-blind, placebo-controlled trial 2012 · cilostazol/l-carnitine · Patients with peripheral artery disease and stable intermittent claudication | 2 g | 180 days | — |
| The effects of magnesium, L-carnitine, and concurrent magnesium-L-carnitine supplementation in migraine prophylaxis 2012 · L-carnitine · patients with migraine | 500 mg | 12 weeks | — |
| Effects of Oral L-Carnitine on Liver Functions after Transarterial Chemoembolization in Intermediate-Stage HCC Patients 2015 · L-carnitine group, BCAA− patients · Japanese adults with intermediate-stage hepatocellular carcinoma and liver cirrhosis undergoing TACE; BCAA− subgroup | 600 mg | 14 weeks | — |
| L-Carnitine to Reduce Chemoradiotherapy-Induced Toxicity in Head and Neck Cancer: A Randomized Study 2025 · study arm · Patients with head and neck squamous cell carcinoma undergoing concurrent chemoradiation | 1.5 g | — | — |
| Long-term effectiveness of carglumic acid in patients with propionic acidemia (PA) and methylmalonic acidemia (MMA): a randomized clinical trial 2021 · standard (control) arm · Children aged 15 years or younger with propionic acidemia or methylmalonic acidemia | 150 mg/kg | 2 years | 17 |
| Cinnoxicam and L-carnitine/acetyl-L-carnitine treatment for idiopathic and varicocele-associated oligoasthenospermia 2004 · group 3 · Adults with idiopathic or varicocele-associated oligoasthenospermia | 2 g | 26 weeks | 106 |
| Cinnoxicam and L-carnitine/acetyl-L-carnitine treatment for idiopathic and varicocele-associated oligoasthenospermia 2004 · group 2 · Adults with idiopathic or varicocele-associated oligoasthenospermia | 2 g | 26 weeks | 101 |
| [A controlled randomized trial of the use of combined L-carnitine and acetyl-L-carnitine treatment in men with oligoasthenozoospermia] 2005 · treatment group · men with oligoasthenozoospermia | 2 g | 90 days | 90 |
| Controlled study on L-carnitine therapeutic efficacy in post-infarction 1992 · L-carnitine group · Adults aged 39–86 years, both sexes, with recent myocardial infarction | 4 g | 1 year | 81 |
| Multi-pharmacological treatment for young subfertile males with chronic prostatitis/chronic pelvic pain syndrome 2024 · group 6 (L-carnitine/Serenoa repens extract) · Males aged 28–40 with chronic prostatitis/chronic pelvic pain syndrome and subfertility | 2 g | 90 days | 50 |
| Multi-pharmacological treatment for young subfertile males with chronic prostatitis/chronic pelvic pain syndrome 2024 · group 7 (tadalafil/L-carnitine/Serenoa repens extract) · Males aged 28–40 with chronic prostatitis/chronic pelvic pain syndrome and subfertility | 2 g | 90 days | 50 |
| Levocarnitine administration in elderly subjects with rapid muscle fatigue: effect on body composition, lipid profile and fatigue 2003 · levocarnitine group · elderly men and women with rapid muscle fatigue following slight physical activity | 4 g | 30 days | 42 |
| The effects of acute L-carnitine supplementation on endurance performance of athletes 2014 · LK-4 · Candidate professional male footballers; age and health condition not stated | 4 g | 1 day | 14 |
| Usefulness of L-carnitine, a naturally occurring peripheral antagonist of thyroid hormone action, in iatrogenic hyperthyroidism: a randomized, double-blind, placebo-controlled clinical trial 2001 · Group A4 · Women receiving a fixed TSH-suppressive dose of L-T4, with iatrogenic hyperthyroidism | 4 g | 60 days | 10 |
| Usefulness of L-carnitine, a naturally occurring peripheral antagonist of thyroid hormone action, in iatrogenic hyperthyroidism: a randomized, double-blind, placebo-controlled clinical trial 2001 · Group B4 · Women receiving a fixed TSH-suppressive dose of L-T4, with iatrogenic hyperthyroidism | 4 g | 120 days | 10 |
| A placebo-controlled double-blind randomized trial of the use of combined l-carnitine and l-acetyl-carnitine treatment in men with asthenozoospermia 2004 · combined l-carnitine and l-acetyl-carnitine treatment · Infertile men aged 20–40 years with oligo-astheno-teratozoospermia and abnormal baseline sperm parameters | 2 g | 26 weeks | — |
| Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia 2005 · Combined L-carnitine and L-acetyl-carnitine · Men aged 20–40 years with idiopathic asthenozoospermia | 2 g | 26 weeks | — |
| Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia 2010 · arm 3 · Patients with cancer-related anorexia/cachexia syndrome; age and sex not reported | 4 g | 120 days | — |
| Randomised phase III clinical trial of 5 different arms of treatment on 332 patients with cancer cachexia 2010 · 3—L-carnitine 4 g/d · Patients with cancer-related anorexia/cachexia syndrome (CACS); age and sex not specified | 4 g | 120 days | — |
| [The evaluation of the antiarrhythmic activity of L-carnitine and propafenone in ischemic cardiopathy] 1993 · Group 1 · Patients with ischemic heart disease and multifocal ventricular extrasystolic arrhythmia; mean age 64 years, 20 men and 10 women across the study | 6 g | 2 weeks | — |
| [The evaluation of the antiarrhythmic activity of L-carnitine and propafenone in ischemic cardiopathy] 1993 · Group 3, combination treatment in the second week · Patients with ischemic heart disease and multifocal ventricular extrasystolic arrhythmia; mean age 64 years, 20 men and 10 women across the study | 6 g | 7 days | — |
| [Therapy of arrhythmia induced by myocardial ischemia. Association of L-carnitine, propafenone and mexiletine] 1995 · Group A · Patients with effort angina and ventricular ectopic beats; age and sex not reported | 6 g | 2 weeks | — |
| [Therapy of arrhythmia induced by myocardial ischemia. Association of L-carnitine, propafenone and mexiletine] 1995 · Group E · Patients with effort angina and ventricular ectopic beats; age and sex not reported | 6 g | 2 weeks | — |
| Effects of L-carnitine supplementation on lipid profiles in patients with coronary artery disease 2016 · LC group · Adults with coronary artery disease; all participants were male, with mean age 71.9 years; diabetes, liver disease and renal disease were excluded. | 1 g | 12 weeks | 20 |
| Effect of PLC on functional parameters and oxidative profile in type 2 diabetes-associated PAD 2006 · PLC group · Patients with type 2 diabetes (NIDDM) associated with peripheral arterial disease | 2 g | 1 year | — |
| Antioxidant treatment for oligoasthenoteratozoospermia and varicocele: a DBPC trial to evaluate the impact of age and body mass index 2024 · supplementation formulation (Proxeed Plus) · Men aged 18–50 years with infertility and oligo-, astheno- and/or teratozoospermia, with or without varicocele | 1 g | 26 weeks | — |
| Adding L-Carnitine and Selenium to Methimazole in Graves' Disease: A Prospective Randomized Trial on Thyroid Markers and Quality of Life 2025 · Intervention Group · Adults with newly diagnosed overt Graves’ disease; mean age 48.51 years; 46 women and 14 men in the study overall | 500 mg | 2 years | 30 |
| Long-term effectiveness of carglumic acid in patients with propionic acidemia (PA) and methylmalonic acidemia (MMA): a randomized clinical trial 2021 · carglumic acid arm · Children aged 15 years or younger with propionic acidemia or methylmalonic acidemia | 150 mg/kg | 2 years | 21 |
| [L-carnitine combined with coenzyme Q10 for idiopathic oligoasthenozoospermia: A double-blind randomized controlled trial] 2018 · LC group · Men with idiopathic oligoasthenozoospermia | 20 mL | 90 days | 62 |
| Effect of L-carnitine on the physical fitness of thalassemic patients 2007 · L-carnitine therapy · Patients with thalassemia major; ages and sex not reported | 50 mg/kg | 26 weeks | 30 |
| Comparative study of the efficacy of captopril, simvastatin, and L-carnitine as cardioprotective drugs in children with type 1 diabetes mellitus: a randomised controlled trial 2021 · L-carnitine group · Children with type 1 diabetes mellitus for more than 3 years; ages and sex not specified | 50 mg/kg | 120 days | 25 |
| Safety and efficacy of clomiphene citrate and L-carnitine in idiopathic male infertility: a comparative study 2010 · group 1 · Men with idiopathic infertility | 25 mg | 90 days | 20 |
| Impact of L-carnitine supplementation on gastric emptying and bowel function in pediatric ketogenic diet therapy: a clinical trial 2024 · Arm I (L-carnitine supplementation group) · Children aged 12 months to 18 years with drug-resistant epilepsy starting ketogenic diet therapy | 50 mg/kg | 90 days | 15 |
| The effects of magnesium, L-carnitine, and concurrent magnesium-L-carnitine supplementation in migraine prophylaxis 2012 · Mg-L-carnitine · patients with migraine | 500 mg | 12 weeks | — |
| l -carnitine adjunct to risperidone for treatment of autism spectrum disorder-associated behaviors: a randomized, double-blind clinical trial 2024 · L-carnitine · Children with confirmed autism spectrum disorder | 150 mg | 10 weeks | — |
| Combined Metabolic Activators Accelerates Recovery in Mild-to-Moderate COVID-19 2021 · CMA group, phase 3 · Adults aged 18–66 with PCR-confirmed mild-to-moderate COVID-19 who did not require hospitalization | 7.46 g | 2 weeks | 229 |
| Combined Metabolic Activators Accelerates Recovery in Mild-to-Moderate COVID-19 2021 · CMA group, phase 2 · Adults aged 19–66 with PCR-confirmed mild-to-moderate COVID-19 who did not require hospitalization | 7.46 g | 2 weeks | 71 |
| [L-carnitine combined with coenzyme Q10 for idiopathic oligoasthenozoospermia: A double-blind randomized controlled trial] 2018 · Combination group · Men with idiopathic oligoasthenozoospermia | 20 mL | 90 days | 63 |
| The effects of concurrent alpha-linolenic acid, L-carnitine supplementation on clinical symptoms, mental health, and quality of life in women with migraine: a randomized, triple-blind, placebo-controlled trial 2025 · Alpha-linolenic plus L-carnitine group · Women aged 20–50 years with migraine | 500 mg | 12 weeks | 40 |
| Ameliorating effects of L-carnitine and synbiotic co-supplementation on anthropometric measures and cardiometabolic traits in women with obesity: a randomized controlled clinical trial 2023 · L-carnitine + synbiotic · Women aged 19–49 with obesity (BMI 30–35 kg/m²), without the listed comorbidities | 1 g | 8 weeks | 23 |
| Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia 2010 · arm 5 · Patients with cancer-related anorexia/cachexia syndrome; age and sex not reported | 4 g | 120 days | — |
| Randomised phase III clinical trial of 5 different arms of treatment on 332 patients with cancer cachexia 2010 · 5—combination of the above · Patients with cancer-related anorexia/cachexia syndrome (CACS); age and sex not specified | 4 g | 120 days | — |
| The effects of concurrent Coenzyme Q10, L-carnitine supplementation in migraine prophylaxis: A randomized, placebo-controlled, double-blind trial 2019 · Coenzyme Q10 and L-carnitine group · Men and women aged 20–40 years with migraine headache | 500 mg | 8 weeks | — |
| Effect of L-carnitine supplementation on lipid profile and apolipoproteins in children on hemodialysis: a randomized placebo-controlled clinical trial 2021 · L-carnitine group · Children aged 6–18 years receiving hemodialysis | 50 mg/kg | 10 weeks | 12 |
| Effects of l-carnitine supplementation on cardiovascular and bone turnover markers in patients with pemphigus vulgaris under corticosteroids treatment: A randomized, double-blind, controlled trial 2019 · L-carnitine group · Patients with pemphigus vulgaris receiving corticosteroid treatment; age and sex not specified | 2 g | 8 weeks | 24 |
| Carbohydrate ingestion augments L-carnitine retention in humans 2007 · Study B, carbohydrate (CHO) trial · Adult men; age and health condition not specified | 3 g | 2 weeks | 14 |
| Carbohydrate ingestion augments L-carnitine retention in humans 2007 · Study B, flavored-water control (Con) trial · Adult men; age and health condition not specified | 3 g | 2 weeks | 14 |
| Carnitine status of pregnant women: effect of carnitine supplementation and correlation between iron status and plasma carnitine concentration 2009 · L-carnitine supplement · Healthy pregnant women, from the 13th week of gestation to term | 500 mg | — | 13 |
| Metabolic changes induced by maximal exercise in human subjects following L-carnitine administration 1990 · L-carnitine · Ten moderately trained male subjects; age and health condition not specified | 2 g | 1 day | 10 |
| Carbohydrate ingestion augments L-carnitine retention in humans 2007 · Study A, carbohydrate (CHO) visit · Adult men; age and health condition not specified | 3 g | 1 day | 8 |
| Carbohydrate ingestion augments L-carnitine retention in humans 2007 · Study A, flavored-water control (Con) visit · Adult men; age and health condition not specified | 3 g | 1 day | 8 |
| Effects of L-carnitine supplement on serum inflammatory cytokines, C-reactive protein, lipoprotein (a), and oxidative stress in hemodialysis patients with Lp (a) hyperlipoproteinemia 2010 · carnitine group · Men and women with hyper-Lp(a) hyperlipoproteinemia receiving hemodialysis | 1 g | 12 weeks | — |
| [Using L- and acetyl-L-carnintines in combination with clomiphene citrate and antioxidant complex for treating idiopathic male infertility: a prospective randomized trial] 2017 · study group · Men aged 25–45 with idiopathic oligo-, astheno- and/or teratozoospermia | 2 g | 120 days | 88 |
| Improvement in insulin resistance and favourable changes in plasma inflammatory adipokines after weight loss associated with two months' consumption of a combination of bioactive food ingredients in overweight subjects 2013 · dietary supplement group · Healthy overweight men and women aged 25–45 years with BMI greater than 25 and less than 35 kg/m² | 300 mg | 8 weeks | 50 |
| A Pilot, Phase II, Observational, Case-Control, 1-Month Study on Asthenopia in Video Terminal Operators without Dry Eye: Contrast Sensitivity and Quality of Life before and after the Oral Consumption of a Fixed Combination of Zinc, L-Carnitine, Extract of Elderberry, Currant and Extract of Eleutherococcus 2021 · group T = treatment · VDT workers of any age and gender, without dry eye and with symptoms of ocular discomfort | 50 mg | 30 days | 15 |
| Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib ± megestrol acetate for patients with cancer-related anorexia/cachexia syndrome 2012 · Arm 1: L-carnitine + celecoxib · Patients with cancer-related anorexia/cachexia syndrome; age and sex not stated | 4 g | 120 days | — |
| Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib ± megestrol acetate for patients with cancer-related anorexia/cachexia syndrome 2012 · Arm 2: L-carnitine + celecoxib + megestrol acetate · Patients with cancer-related anorexia/cachexia syndrome; age and sex not stated | 4 g | 120 days | — |
| Effects of Oral L-Carnitine on Liver Functions after Transarterial Chemoembolization in Intermediate-Stage HCC Patients 2015 · L-carnitine group, BCAA+ patients · Japanese adults with intermediate-stage hepatocellular carcinoma and liver cirrhosis undergoing TACE; already receiving BCAA granules | 600 mg | 14 weeks | — |
| Potential inhibitory effects of L-carnitine supplementation on tissue advanced glycation end products in patients with hemodialysis 2013 · L-carnitine · Hemodialysis patients with total carnitine levels below 50 μmol/L | 900 mg | 26 weeks | 51 |
| A randomised, double-blind, placebo-controlled trial of L-carnitine in suspected acute myocardial infarction 1996 · carnitine group · Patients with suspected acute myocardial infarction; age and sex not reported | 2 g | 4 weeks | 51 |
| The effect of L-carnitine on plasma lipoprotein(a) levels in hypercholesterolemic patients with type 2 diabetes mellitus 2003 · L-carnitine group · Adults with newly diagnosed type 2 diabetes managed with dietary restriction and hypercholesterolemia; mean age 52 years | 2 g | 26 weeks | 46 |
| [Use of L-carnitine before percutaneous epididymal sperm aspiration-intracytoplasmic sperm injection for obstructive azoospermia] 2010 · L-carnitine group · Men with obstructive azoospermia; age not reported | 2 g | 90 days | 43 |
| L-Carnitine supplementation reduces oxidized LDL cholesterol in patients with diabetes 2009 · L-carnitine group · Adults with type 2 diabetes | 2 g | 90 days | 41 |
| Effect of L-carnitine on the size of low-density lipoprotein particles in type 2 diabetes mellitus patients treated with simvastatin 2009 · L-carnitine and simvastatin group · Adults with type 2 diabetes treated with simvastatin | 2 g | 90 days | 40 |
| Effects of l-Carnitine Supplementation on Serum Inflammatory Factors and Matrix Metalloproteinase Enzymes in Females with Knee Osteoarthritis: A Randomized, Double-Blind, Placebo-Controlled Pilot Study 2016 · L-carnitine group · Females with mild to moderate knee osteoarthritis | 750 mg | 8 weeks | 36 |
| Effects of L-carnitine supplementation in patients with mild-to-moderate COVID-19 disease: a pilot study 2022 · intervention group · Adults aged 18–60 hospitalized with mild-to-moderate COVID-19 | 3 g | 5 days | 33 |
| The effects of L-carnitine supplementation on inflammation, oxidative stress, and clinical outcomes in critically Ill patients with sepsis: a randomized, double-blind, controlled trial 2024 · L-carnitine group · Adults older than 18 years with sepsis admitted to an ICU and receiving enteral nutrition; men and women | 3 g | 7 days | 30 |
| L-Carnitine/Simvastatin Reduces Lipoprotein (a) Levels Compared with Simvastatin Monotherapy: A Randomized Double-Blind Placebo-Controlled Study 2017 · L-carnitine plus simvastatin · People with mixed hyperlipidemia and elevated Lp(a), with LDL-C >160 mg/dL, TAG >150 mg/dL and Lp(a) >20 mg/dL; age and sex not specified | 2 g | 12 weeks | 29 |
| The effects of l-Carnitine supplementation on inflammatory markers, clinical status, and 28 days mortality in critically ill patients: A double-blind, randomized, placebo-controlled trial 2022 · l-Carnitine group · Critically ill patients admitted to the intensive care unit; age and sex not specified | 3 g | 7 days | 27 |
| The effects of adjunctive treatment with L-carnitine on monitoring laboratory variables in ICU patients: a double-blinded randomized controlled clinical trial 2023 · L-carnitine group · Critically ill adults older than 18 years admitted to general ICUs; mixed underlying diagnoses | 3 g | 7 days | 27 |
| Efficacy and tolerability of combined treatment with L-carnitine and simvastatin in lowering lipoprotein(a) serum levels in patients with type 2 diabetes mellitus 2006 · Simvastatin plus L-carnitine · Patients with type 2 diabetes mellitus | 2 g | 60 days | 26 |
| l-carnitine downregulate the muscle wasting effect of glucocorticoids in pemphigus patient: A randomized double-blind placebo-controlled study 2023 · l-carnitine group · Adults aged 30–65 with pemphigus under corticosteroid therapy | 2 g | 8 weeks | 24 |
| Antiinflammatory effects of L-carnitine supplementation (1000 mg/d) in coronary artery disease patients 2015 · LC group · Patients with coronary artery disease, identified by cardiac catheterization as having <50% stenosis of one major coronary artery; age and sex not specified | 1 g | 12 weeks | 23 |
| Effects of L-carnitine supplementation on oxidative stress and antioxidant enzymes activities in patients with coronary artery disease: a randomized, placebo-controlled trial 2014 · LC group · Men, mean age about 72 years, with coronary artery disease (CAD) | 1 g | 12 weeks | 20 |
| L-carnitine reduces plasma lipoprotein(a) levels in patients with hyper Lp(a) 2000 · L-carnitine group · People with Lp(a) levels of 40–80 mg/dL, most with concomitant elevated LDL cholesterol and triglycerides; age and sex not reported | 2 g | — | 18 |
| L-carnitine and creatine in Friedreich's ataxia. A randomized, placebo-controlled crossover trial 2005 · L-carnitine · Patients with genetically confirmed Friedreich's ataxia | 3 g | 120 days | 16 |
| Effect of carnitine on muscular glutamate uptake and intramuscular glutathione in malignant diseases 2000 · L-carnitine group · Well-nourished patients aged 20–75 with carcinoma of the stomach, colon, liver, pancreas, kidney, or lung | 2 g | 5 days | 14 |
| Effects of acute L-carnitine supplementation on nitric oxide production and oxidative stress after exhaustive exercise in young soccer players 2015 · 3 g L-carnitine group · Healthy male soccer players aged 17–19 years | 3 g | 1 day | 13 |
| Short-term carnitine supplementation does not augment LCPomega3 status of vegans and lacto-ovo-vegetarians 2005 · Group A, weeks 1–4 · Apparently healthy vegans and lacto-ovo-vegetarians | 990 mg | 4 weeks | 11 |
| L-Carnitine L-tartrate supplementation favorably affects markers of recovery from exercise stress 2002 · LCLT supplement · Resistance-trained men; age and health condition not specified | 2 g | 3 weeks | 10 |
| The effects of L-carnitine L-tartrate supplementation on hormonal responses to resistance exercise and recovery 2003 · L-carnitine L-tartrate (LCLT) supplementation · Healthy, recreationally weight-trained men, mean age 23.7 years | 2 g | 3 weeks | 10 |
| Androgenic responses to resistance exercise: effects of feeding and L-carnitine 2006 · L-carnitine L-tartrate (LCLT) · Resistance-trained men; mean age 22 years | 2 g | 3 weeks | 10 |
| Antioxidant treatment associated with sildenafil reduces monocyte activation and markers of endothelial damage in patients with diabetic erectile dysfunction: a double-blind, placebo-controlled study 2007 · PLC alone · Adults with type 2 diabetes and erectile dysfunction; sex and age range not reported | 2 g | 12 weeks | 8 |
| Antioxidant treatment associated with sildenafil reduces monocyte activation and markers of endothelial damage in patients with diabetic erectile dysfunction: a double-blind, placebo-controlled study 2007 · PLC plus sildenafil · Adults with type 2 diabetes and erectile dysfunction; sex and age range not reported | 2 g | 12 weeks | 8 |
| Low Bioavailability and High TMAO Production: Novel Insights Into Acetylcarnitine and Carnitine Metabolism 2025 · Carnitine repeated · Healthy adult volunteers, men and women; no stated disease | 2.42 g | 7 days | 6 |
| Use of carnitine therapy in selected cases of male factor infertility: a double-blind crossover trial 2003 · L-carnitine therapy · Infertile men aged 20–40 years selected for abnormal baseline sperm parameters | 2 g | 60 days | — |
| Effect of L-carnitine on plasma glycemic and lipidemic profile in patients with type II diabetes mellitus 2005 · L-carnitine group · Adults with type II diabetes; 22 men and 13 women across the study, mean age 51.3 years | 3 g | 12 weeks | — |
| L-carnitine treatment reduces steatosis in patients with chronic hepatitis C treated with alpha-interferon and ribavirin 2008 · Group B · Patients with chronic hepatitis C treated with interferon alpha and ribavirin | 2 g | 1 year | — |
| Carbohydrate, protein, and fat metabolism during exercise after oral carnitine supplementation in humans 2008 · L-carnitine L-tartrate (LC) group · Active nonvegetarian males; age and health condition not specified | 2 g | 2 weeks | — |
| Oxidative stress in response to aerobic and anaerobic power testing: influence of exercise training and carnitine supplementation 2009 · GPLC-1 · 32 subjects; age, sex, and health condition not specified | 1 g | 8 weeks | — |
| Oxidative stress in response to aerobic and anaerobic power testing: influence of exercise training and carnitine supplementation 2009 · GPLC-3 · 32 subjects; age, sex, and health condition not specified | 3 g | 8 weeks | — |
| Effects of combination of sibutramine and L-carnitine compared with sibutramine monotherapy on inflammatory parameters in diabetic patients 2011 · sibutramine plus L-carnitine · Patients with uncontrolled type 2 diabetes mellitus (HbA1c >8.0%) receiving oral hypoglycemic agents or insulin; age and sex not reported | 2 g | 1 year | — |
| Orlistat and L-carnitine compared to orlistat alone on insulin resistance in obese diabetic patients 2010 · orlistat plus L-carnitine · Adults with uncontrolled type 2 diabetes mellitus (HbA1c > 8.0%) receiving oral hypoglycemic agents or insulin | 2 g | 1 year | — |
| Effects of L-Carnitine supplement on plasma coagulation and anticoagulation factors in hemodialysis patients 2010 · carnitine group · Hemodialysis patients; age range and sex not reported | 1 g | 12 weeks | — |
| Effects of l-carnitine supplement on serum amyloid A and vascular inflammation markers in hemodialysis patients: a randomized controlled trial 2011 · carnitine group · Adults with end-stage kidney disease receiving hemodialysis; ages not reported; 15 men and 21 women across the study | 1 g | 12 weeks | — |
| Effect of lysine, vitamin B(6), and carnitine supplementation on the lipid profile of male patients with hypertriglyceridemia: a 12-week, open-label, randomized, placebo-controlled trial 2012 · carnitine group · Adult Lebanese men with hypertriglyceridemia, approximately 50 years old | 1 g | 12 weeks | — |
| A pilot trial of l-carnitine in patients with traumatic brain injury: Effects on biomarkers of injury 2018 · LCA+ group · Patients with severe traumatic brain injury | 2 g | 7 days | — |
| Comparative study to evaluate the effect of l-carnitine plus glimepiride versus glimepiride alone on insulin resistance in type 2 diabetic patients 2019 · glimepiride plus l-carnitine (group 2) · Adults with type 2 diabetes who had not achieved glycemic goals on glimepiride monotherapy | 2 g | 26 weeks | — |
| L-Carnitine supplementation reduces biomarkers of inflammatory and oxidative stress in patients with coronary artery disease: a randomised controlled trial 2023 · LC · Patients with coronary artery disease (CAD); age range and sex not reported | 1 g | 90 days | — |
| L-Carnitine Tartrate Supplementation for 5 Weeks Improves Exercise Recovery in Men and Women: A Randomized, Double-Blind, Placebo-Controlled Trial 2021 · L-carnitine supplementation group (CAR) · Healthy men and women aged 21–65 years who participated in moderate physical activity at least 3 days per week | 3 g | 37 days | — |
| The effect of L-carnitine supplementation on insulin resistance, sex hormone-binding globulin and lipid profile in overweight/obese women with polycystic ovary syndrome: a randomized clinical trial 2022 · L-carnitine group · Overweight or obese reproductive-age women with polycystic ovary syndrome (PCOS) | 1 g | 12 weeks | — |
| L-Carnitine and synbiotic co-supplementation: beneficial effects on metabolic-endotoxemia, meta-inflammation, and oxidative-stress biomarkers in obese patients: a double blind, randomized, controlled clinical trial 2023 · L-carnitine mono-therapy with maltodextrin placebo · Obese female patients; age range not reported | 1 g | 8 weeks | — |
| Skeletal muscle carnitine loading increases energy expenditure, modulates fuel metabolism gene networks and prevents body fat accumulation in humans 2013 · Carnitine · Healthy males; age not reported | 2.72 g | 12 weeks | 6 |
| Carnitine depletion in peripheral blood mononuclear cells from patients with AIDS: effect of oral L-carnitine 1994 · L-carnitine · men with advanced AIDS (CDC stage IVCI) and normal serum carnitine levels | 6 g | 2 weeks | — |
| L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN)--a randomized multicentre trial 2012 · L-Carnitine · Adults with advanced, irresectable UICC Stage IV pancreatic adenocarcinoma; mean age 64.4 years, both sexes | 4 g | 12 weeks | 38 |
| Effect of carni Q-gel (ubiquinol and carnitine) on cytokines in patients with heart failure in the Tishcon study 2007 · group A (carni Q-gel) · Patients with class II–IV heart failure | 2.25 g | 12 weeks | 31 |
| [Antioxidant therapeutic efficiency after the use of carnitine in infertile patients with bacterial or non bacterial prostato-vesiculo-epididymitis] 2001 · B1 · Infertile men with bacterial PVE, mean age 35 years (range 28–38) | 2 g | 90 days | 23 |
| [Antioxidant therapeutic efficiency after the use of carnitine in infertile patients with bacterial or non bacterial prostato-vesiculo-epididymitis] 2001 · B2 · Infertile men with bacterial PVE, mean age 35 years (range 28–38) | 2 g | 90 days | 16 |
| [Antioxidant therapeutic efficiency after the use of carnitine in infertile patients with bacterial or non bacterial prostato-vesiculo-epididymitis] 2001 · A1 · Infertile men with abacterial prostato-vesiculo-epididymitis (PVE), mean age 34 years (range 27–40) | 2 g | 90 days | 14 |
| Effects of acute L-carnitine supplementation on nitric oxide production and oxidative stress after exhaustive exercise in young soccer players 2015 · 4 g L-carnitine group · Healthy male soccer players aged 17–19 years | 4 g | 1 day | 13 |
| [Antioxidant therapeutic efficiency after the use of carnitine in infertile patients with bacterial or non bacterial prostato-vesiculo-epididymitis] 2001 · B3 · Infertile men with bacterial PVE, mean age 35 years (range 28–38) | 2 g | 90 days | 12 |
| [Antioxidant therapeutic efficiency after the use of carnitine in infertile patients with bacterial or non bacterial prostato-vesiculo-epididymitis] 2001 · A2 · Infertile men with abacterial PVE, mean age 34 years (range 27–40) | 2 g | 90 days | 8 |
| [Antioxidant therapeutic efficiency after the use of carnitine in infertile patients with bacterial or non bacterial prostato-vesiculo-epididymitis] 2001 · A3 · Infertile men with abacterial PVE, mean age 34 years (range 27–40) | 2 g | 90 days | 8 |
| Caloric restriction and L-carnitine administration improves insulin sensitivity in patients with impaired glucose metabolism 2010 · group LC · Adults with impaired fasting glucose or type 2 diabetes mellitus | 4 g | 10 days | 8 |
| Effects of L-carnitine in patients with hepatic encephalopathy 2005 · group A · Patients with hepatic encephalopathy and cirrhosis; ages and sex not reported | 4 g | 90 days | — |
| L-Carnitine and synbiotic co-supplementation: beneficial effects on metabolic-endotoxemia, meta-inflammation, and oxidative-stress biomarkers in obese patients: a double blind, randomized, controlled clinical trial 2023 · L-carnitine + synbiotic co-supplementation · Obese female patients; age range not reported | 1 g | 8 weeks | — |
| Modulatory Effects of Multi-species/Multi-strain Synbiotic and L-carnitine Concomitant Supplementation on Atherogenic-Indices, Body Composition, Visceral Obesity, and Appetite in Metabolically Healthy Women with Obesity: A Double-Blind Randomized Controlled Clinical Trial 2025 · co-supplementation · Metabolically healthy women with obesity | 1 g | 8 weeks | — |
| A prospective double-blind, randomized clinical trial of levocarnitine to treat autism spectrum disorders 2011 · L-carnitine group · Children aged 3–10 years with autism spectrum disorder | 50 mg/kg | 90 days | 20 |
| Chronic oral ingestion of L-carnitine and carbohydrate increases muscle carnitine content and alters muscle fuel metabolism during exercise in humans 2011 · Carnitine · Healthy men, mean age 25.9 years | 4 g | 24 weeks | — |
| Effects of levocarnitine on brachial-ankle pulse wave velocity in hemodialysis patients: a randomized controlled trial 2014 · L-carnitine therapy group · Adults aged 20–85 years receiving hemodialysis with plasma free carnitine concentration below 40 μmol/L | 20 mg/kg | 1 year | 88 |
| Levocarnitine Improves Cardiac Function in Hemodialysis Patients With Left Ventricular Hypertrophy: A Randomized Controlled Trial 2016 · levocarnitine group · Adults with carnitine deficiency undergoing maintenance hemodialysis | 20 mg/kg | 1 year | 75 |
| Comparison of L-Carnitine vs. Coq10 and Vitamin E for idiopathic male infertility: a randomized controlled trial 2022 · study group · men with asthenozoospermia and teratozoospermia | 30 g | 90 days | 73 |
| Effect of Levocarnitine on the Therapeutic Efficacy of Conventional Therapy in Children with Dilated Cardiomyopathy: Results of a Randomized Trial in 29 Children 2018 · Experimental group · Children aged 1 month to 13 years with dilated cardiomyopathy and NYHA class III–IV cardiac function | 50 mg/kg | 1 year | 19 |
| Effect of L-Carnitine Supplementation on Inflammatory Markers and Serum Glucose in Hemodialysis Children: A Randomized, Placebo-Controlled Clinical Trial 2022 · L-carnitine · Children aged 6–18 years receiving hemodialysis | 50 mg/kg | 10 weeks | 12 |
| Carnitine status of pediatric patients on continuous ambulatory peritoneal dialysis 1990 · Group 2 · Pediatric patients receiving continuous ambulatory peritoneal dialysis (CAPD) | 100 mg/kg | 60 days | — |
| Effects of Low Doses of L-Carnitine Tartrate and Lipid Multi-Particulate Formulated Creatine Monohydrate on Muscle Protein Synthesis in Myoblasts and Bioavailability in Humans and Rodents 2021 · Dose A · Healthy adults aged 18–30 years, male and female, without chronic disease | 500 mg | 1 day | 15 |
| Effects of Low Doses of L-Carnitine Tartrate and Lipid Multi-Particulate Formulated Creatine Monohydrate on Muscle Protein Synthesis in Myoblasts and Bioavailability in Humans and Rodents 2021 · Dose B · Healthy adults aged 18–30 years, male and female, without chronic disease | 500 mg | 1 day | 15 |
| Effects of Low Doses of L-Carnitine Tartrate and Lipid Multi-Particulate Formulated Creatine Monohydrate on Muscle Protein Synthesis in Myoblasts and Bioavailability in Humans and Rodents 2021 · Dose C · Healthy adults aged 18–30 years, male and female, without chronic disease | 500 mg | 1 day | 15 |
| [L-carnitine: safe and effective for asthenozoospermia] 2010 · Group A · Men with asthenozoospermia | 2 g | 90 days | 68 |
| [Huanshao Capsules combined with levocarnitine for the treatment of asthenospermia, oligospermia and teratozoospermia] 2018 · HSC+LC group · Men with infertility and spleen and kidney asthenia; age not reported | 30 mL | 12 weeks | 60 |
| Short-term carnitine supplementation does not augment LCPomega3 status of vegans and lacto-ovo-vegetarians 2005 · Group A, weeks 5–8 · Apparently healthy vegans and lacto-ovo-vegetarians | 990 mg | 4 weeks | 11 |
| Short-term carnitine supplementation does not augment LCPomega3 status of vegans and lacto-ovo-vegetarians 2005 · Group B, weeks 5–8 · Apparently healthy vegans and lacto-ovo-vegetarians | 990 mg | 4 weeks | 9 |
| An Exploratory Investigation of Endotoxin Levels in Novice Long Distance Triathletes, and the Effects of a Multi-Strain Probiotic/Prebiotic, Antioxidant Intervention 2016 · LAB4 ANTI · Recreationally active adults aged about 35 years, 25 men and 5 women in the overall study cohort, training for their first long-distance triathlon | 600 mg | 90 days | — |
| [Huanshao Capsules combined with levocarnitine for the treatment of asthenospermia, oligospermia and teratozoospermia] 2018 · Levocarnitine group · Men with infertility and spleen and kidney asthenia; age not reported | 30 mL | 12 weeks | 59 |
| Modulatory Effects of Multi-species/Multi-strain Synbiotic and L-carnitine Concomitant Supplementation on Atherogenic-Indices, Body Composition, Visceral Obesity, and Appetite in Metabolically Healthy Women with Obesity: A Double-Blind Randomized Controlled Clinical Trial 2025 · mono-therapy · Metabolically healthy women with obesity | 1 g | 8 weeks | — |